Does Rallies show Form 4 insider transactions for CGTX?

Yes. Rallies tracks CGTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CGTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CGTX. It does not provide personalized investment advice.

CGTX (Cognition Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Cognition Therapeutics, Inc. Common Stock (CGTX) is a publicly traded Healthcare sector company. As of May 21, 2026, CGTX trades at $1.25 with a market cap of $97.55M and a P/E ratio of -3.98. CGTX moved +15.32% today. Year to date, CGTX is -7.86%; over the trailing twelve months it is +281.43%. Its 52-week range spans $0.22 to $3.83. Analyst consensus is buy with an average price target of $3.50. Rallies surfaces CGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CGTX stock inside the company?

Recent CGTX insider activity includes Doyle John Brendan bought 10.00K, Ricciardi Lisa bought 9.18K, Caggiano Anthony bought 10.00K, Ricciardi Lisa bought 38.85K, and Ricciardi Lisa bought 5.70K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CGTX Key Metrics

Key financial metrics for CGTX
Metric	Value
Price	$1.25
Market Cap	$97.55M
P/E Ratio	-3.98
EPS	$-0.32
Dividend Yield	0.00%
52-Week High	$3.83
52-Week Low	$0.22
Volume	34.92K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-23.49M
Gross Margin	0.00%

Recent CGTX Insider Trades

Doyle John Brendan bought 10.00K (~$11.30K) on Apr 16, 2026.
Ricciardi Lisa bought 9.18K (~$10.09K) on Apr 16, 2026.
Caggiano Anthony bought 10.00K (~$11.10K) on Apr 16, 2026.
Ricciardi Lisa bought 38.85K (~$30.00K) on Jan 31, 2025.
Ricciardi Lisa bought 5.70K (~$9.97K) on Mar 14, 2024.

Latest CGTX News

Cognition Therapeutics Secures FDA Path Forward for Zervimesine Registrational DLB Psychosis Study — May 21, 2026
Two Hantavirus Deaths Spotlight Therapy Gap, Elevating CGTX Antiviral Pipeline — May 12, 2026
Cognition Therapeutics Q1 Loss Narrows to $4.6M, FDA Meeting Set for DLB Psychosis — May 7, 2026
Cognition Therapeutics to Present CT1812 Data, Initiate Late-Stage DLB Psychosis Study on April 13 — Apr 7, 2026
Cognition Therapeutics Secures Cash Through Q2 2027, Advances Zervimesine DLB Trials — Mar 26, 2026

CGTX Analyst Consensus

2 analysts cover CGTX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.50.

Common questions about CGTX

Who is trading CGTX stock inside the company?: Recent CGTX insider activity includes Doyle John Brendan bought 10.00K, Ricciardi Lisa bought 9.18K, Caggiano Anthony bought 10.00K, Ricciardi Lisa bought 38.85K, and Ricciardi Lisa bought 5.70K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CGTX?: Yes. Rallies tracks CGTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CGTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CGTX. It does not provide personalized investment advice.